Cyclacel announces notice of intention to grant new european patent covering plogosertib pharmaceutical compositions

Berkeley heights, n.j., june 26, 2024 (globe newswire) -- cyclacel pharmaceuticals, inc. (nasdaq: cycc, nasdaq: cyccp; "cyclacel" or the "company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the receipt of a notice from the european patent office of the intention to grant a patent which includes claims to novel pharmaceutical compositions of plogosertib, a plk1 inhibitor.
CYCC Ratings Summary
CYCC Quant Ranking